Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Washington: - Valley Medical Center — Renton, Washington
- Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Washington: - Research Site — Tacoma, Washington
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Washington: - Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010) — Spokane, Washington
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Washington: - University of Washington — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Washington: - Vista Oncology ( Site 5449) — Olympia, Washington
- Medical Oncology Associates, PS ( Site 5406) — Spokane, Washington
Phase 3 Recruiting Industry
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who h…
Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT07342478
Sites in Washington: - Medical Oncology Associates - Spokane — Spokane, Washington
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Sites in Washington: - Study Site 103 — Tacoma, Washington
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Washington: - Overlake Medical Center — Bellevue, Washington
- Valley Medical Center — Renton, Washington
- Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
- Providence Saint Mary Regional Cancer Center — Walla Walla, Washington
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- University of Washington Medical Center — Seattle, Washington
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Industry
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for st…
Sponsor: AstraZeneca
NCT ID: NCT05952024
Sites in Washington: - Research Site — Olympia, Washington
- Research Site — Tacoma, Washington
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT07015242
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants w…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Washington: - Research Site — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transform…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04728893
Sites in Washington: - Medical Oncology Associates (Summit Cancer Centers) ( Site 2710) — Spokane, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in Washington: - Research Site — Seattle, Washington
Phase 2 Recruiting Academic/Other
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete resp…
Sponsor: Providence Health & Services
NCT ID: NCT06175000
Sites in Washington: - Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Sponsor: BeOne Medicines
NCT ID: NCT06697184
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolen…
Sponsor: Enterome
NCT ID: NCT04669171
Sites in Washington: - University of Washington-Seattle Cancer Care Alliance — Seattle, Washington